Table 1.
The basic characteristics of eligible patients in ATO and RIF groups.
| Total N = 176 |
ATO groups N = 85 |
RIF groups N = 91 |
p | |
|---|---|---|---|---|
| Median age, years (range) | 8.2 (1.0,15.9) | 7.9 (1.0,14.6) | 8.8 (1.5,16.6) | 0.613 |
| Male, n (%) | 105 (59.7) | 57 (67.1) | 48 (52.7) | 0.053 |
| Median WBC, ×109/L (range) | 4.5 (0.3,228.0) | 4.4 (0.3,228.0) | 4.8 (0.8,74.7) | 0.876 |
| Median PLT, ×109/L (range) | 25.5 (4.0,226.0) | 26.5 (4.0,135.0) | 24.0 (4.0,226.0) | 0.723 |
| Median Hb, g/L (range) | 74.5 (31.0,141.0) | 74.0 (31.0,131.0) | 76.0 (37.0,141.0) | 0.321 |
| Sanz risk, n (%), | ||||
| Low-risk | 34 (19.3) | 15 (17.6) | 19 (20.9) | 0.804 |
| Intermediate-risk | 85 (48.3) | 43 (50.6) | 42 (46.2) | |
| High-risk | 57 (32.4) | 27 (31.8) | 30 (32.9) | |
| CNSL at diagnosis | 0 | 0 | 0 | |
WBC white blood cell count, PLT platelet counts, Hb hemoglobin level, Low-risk APL WBC ≤ 10 × 109/L and PLT ≥ 40 × 109/L, intermediate-risk WBC ≤ 10×109/L and PLT < 40 × 109/L, high-risk WBC > 10 × 109/L at diagnosis, CNSL central nervous system leukemia defined as having clinical signs of facial nerve palsy, hypothalamic syndrome, etc., and/or MRI evidence of intracranial, intradural mass.